Company profile
BIOGEN INC.
NASDAQ:BIIBBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (33)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DACLIZUMAB | approved | — | 1 | approved |
| DIMETHYL FUMARATE | approved | — | 34 | approved |
| DIROXIMEL FUMARATE | approved | — | 5 | approved |
| INTERFERON BETA-1A | approved | — | 18 | approved |
| NATALIZUMAB | approved | — | 31 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (411)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00664573 | phase2 | terminated | 2007-11-01 | 2008-10-01 | Biogen | 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants |
| NCT02477800 | phase3 | terminated | 2015-08-13 | 2019-08-08 | Biogen | 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease |
| NCT02484547 | phase3 | terminated | 2015-09-15 | 2019-08-05 | Biogen | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease |
| NCT03070132 | phase3 | withdrawn | 2023-04-19 | 2025-10-14 | Biogen | 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia |
| NCT03637387 | phase3 | withdrawn | 2023-03-01 | 2025-08-18 | Biogen | 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia |
FDA applications (13)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103628 | BLA | Biogen Inc. | ||||
Loading… | ||||||
| BLA 103737 | BLA | IDEC Pharmaceuticals Corp. | ||||
Loading… | ||||||
| BLA 125104 | BLA | Biogen Inc. | ||||
Loading… | ||||||
| BLA 125499 | BLA | Biogen Inc. | ||||
Loading… | ||||||
| BLA 761029 | BLA | Biogen Inc. | ||||
Loading… | ||||||